Clinical trials are one of those things that no one really cares about until you need to. In the UK we have a pretty impressive cancer trial landscape that’s recognised
The Patience and Patients of Clinical Trials…
METUPUK Breast Cancer Awareness 2024 for metastatic breast cancer
METUPUK’ Breast Cancer Awareness Month campaign for October across the UK and on social media channels. Continuing the synergy with The Darker Side of Pink travelling campaign highlighting the 31 women a
Breast cancer patients denied life-extending drug by NICE
A cancer drug which received standing ovation from the Global Medical Community is being withheld from NHS breast cancer patients. METUPUK are devastated by NICE decision not to recommend the drug
METUPUK joins the Northern Ireland Cancer Charities Coalition
METUPUK has joined the Northern Ireland Coalition (NICCC) and will work collaboratively with partner charities to improve outcomes for cancer patients in Northern Ireland. Ann McBrien, METUPUK’s Northern Ireland Executive
Data collection for metastatic breast cancer, “we are only counted when we are dead” – Kat Southwell
Just shy of six years ago I was diagnosed with Inflammatory Breast Cancer (IBC). Rare with a “high fatality rate and difficult to treat” is what I learnt in the
Drugs drugs everywhere, can you access ones that work? Kirstin Spencer
Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge
METUPUK at the UK Interdisciplinary Breast Cancer Symposium
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a
NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
On the trail of a Clinical Trial…
METUPUK historically maintained their own in-house clinical trial database for metastatic trials in the UK as there was no one source that contained them all. It used the key sites used across the UK; Cancer Research UK, Be Part of Research, ISRCTN and ClinicalTrials.gov.
Leaping forward to 2022, surely by now one of them must be THE accurate, easily searchable source of breast cancer trials? If not, how do our oncologists quickly and accurately find the best trials for their metastatic patients?
And where do patients start when looking for a metastatic trial themselves?
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)